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OBJECTIVE: The conventional single cohort approach
considers the impact of a change in screening policy only
on those who are about to enter the screening age range.
The multiple cohort simulation models the effect of
screening on the whole age-range affected by any policy
change, and takes into account the actual age distribution
in the population. We examined the effect of a single 
and a multiple birth cohort simulation on the incremen-
tal cost-effectiveness estimates of a cervical screening
program, comparing a two-yearly with a three-yearly
screening policy. METHODS: We use a 20-state Markov
model of the natural progression of cervical cancer and
pre-cancerous lesions for unscreened women developed
by the Duke University and adapted to the Australian
health care system. This model was modiﬁed with the
help of lookup tables to allow running 11 cohorts start-
ing at 5-year intervals. In the multiple cohort model, costs
and effects of each birth cohort are aggregated into a
weighted average, according to the proportion of each age
group in the target female population. RESULTS: Costs
and effects are both 15% lower in the multiple cohort
simulation, which is an expected result given the higher
average age in that group. Compared with a single birth
cohort simulation, the incremental cost-effectiveness of a
shift from two-yearly to three-yearly screening was 30%
higher when using the multiple cohort simulation:
AU$61,031 versus AU$47,361 per life year. So a policy-
shift from two-yearly to three-yearly screening is less cost-
effective in the multiple cohort simulation. Using different
age structures of four countries had very little impact on
the cost-effectiveness ratios: AU$61,690 for the USA,
AU$62,398 for the UK and AU$62,795 for Japan. CON-
CLUSION: Future modelling-based evaluations of screen-
ing policies should take greater account of the time
horizon of the decision, and also the age-range of the pop-
ulation that is targeted.
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OBJECTIVES: The topic of discounting health outcomes
in economic evaluations has led to much debate in the
ﬁeld of health technology assessment. In practice, health
outcomes are mainly discounted by means of the contro-
versial discounted utility (DU) model. When adopting an
individual perspective, as recommended by new welfare
economic theory, the main reason for discounting health
is uncertainty of the individual about the future. This
uncertainty is directly related to future health and, ulti-
mately, the occurrence and timing of death. The purpose
of this study is to examine the relevance of explicitly
including life expectancy in models of discounting.
METHODS: Aspects and assumptions that are relevant
for life expectancy and discounting health: a) the future
is not fully uncertain and individuals are aware of their
life expectancy; b) trade-offs among beneﬁts occurring at
different points in time will result in choosing to receive
health beneﬁts before the moment with a high probabil-
ity of being dead; and c) when the life expectancy of a
(patient) population is known, it is possible to identify
(time) cut-off points for individuals at which the proba-
bility of being alive is high, or at which the probability
of being dead is high. These points in time distinctively
inﬂuence the level of discounting. RESULTS: The stan-
dard DU model, which is insensitive to variation in life
expectancy, was compared with an alternative model of
discounting that explicitly includes life expectancy. In 
the current example, focusing on patients with a life
expectancy of 10 years, the alternative model led to
higher present values of future health outcomes when the
time horizon was less than 8 years. CONCLUSIONS:
Explicitly including life expectancy in models of dis-
counting seems to address some of the controversy sur-
rounding the discounting of health outcomes. Empirical
studies are needed to further explore the inﬂuence of life
expectancy on individual time preferences.
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OBJECTIVES: Chronic obstructive pulmonary disease
(COPD) is a major cause of mortality and morbidity in
Europe. This study will review and criticise available
information about epidemiological ﬁgures, cost of care
and cost or cost-effectiveness of therapeutic interventions
for COPD published in European countries. METHODS:
Literature search via PUBMED, EMBASE and Cochrane
Society was systematically conducted (covering January
1990 to March 2003) using the search terms: COPD, res-
piratory disease, epidemiology, incidence, prevalence,
treatment, costs and cost analysis, cost-of-illness, cost-
effectiveness, pharmacoeconomics. RESULTS: Of 479
matching articles, which were found for the epidemiology
review, only 9 studies were considered. These were cross-
sectional, population-based epidemiological studies with
precise epidemiologic information about the country or
